GlassScriptPhysician profile
Benjamin W Kurz
NPI 1710229596
$6,379.30
in general payments reported to CMS, 2019-2025
37 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $625 · 2021: $881 · 2022: $1,563 · 2023: $699 · 2024: $840 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.17 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,632.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $738.84 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $618.32 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $467.54 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $368.20 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $267.59 | 2019-2025 | |
| Ardelyx, INC. | $213.69 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $210.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $191.26 | 2022-2025 | |
| Allergan, INC. | $157.86 | 2019 | |
| Qol Medical, LLC | $152.91 | 2019-2025 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $133.84 | 2022 | |
| Intercept Pharmaceuticals, INC. | $132.03 | 2019-2022 | |
| Redhill Biopharma INC. | $122.00 | 2020-2022 | |
| Gilead Sciences, INC. | $116.93 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $115.49 | 2022-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $87.97 | 2019-2024 | Rebyota |
| Celltrion USA INC. | $74.82 | 2024-2025 | Vegzelma |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Daiichi Sankyo INC. | $64.52 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $53.22 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.43 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $42.49 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $38.54 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $33.99 | 2022 | |
| Medtronic, INC. | $32.32 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $26.71 | 2019-2023 | Dificid |
| Boston Scientific Corporation | $25.60 | 2019-2022 | |
| Amgen INC. | $22.34 | 2022 | |
| Shionogi INC | $22.16 | 2019 | |
| Shire North American Group INC | $19.57 | 2019 | |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $16.75 | 2025 | Iqirvo |
| Concordia Pharmaceuticals INC. | $16.42 | 2019 | |
| Dynavax Technologies Corporation | $15.47 | 2019 | |
| Axonics, INC. | $12.86 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,125.31 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kurz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.